Progyny PGNY
$35.71 +$0.26 (+0.73%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $35.14 -1.60%
Open$35.52
Prev close$35.45
Day range$35.50 – $36.08
Volume1.11M
Market cap$2.63B
P/E (TTM)32.8
Dividend yield–
PGNY Stock News
Headlines matching Progyny or the PGNY ticker, most recent first.
- Citizens JMP Maintains Progyny(PGNY.US) With Buy Rating, Raises Target Price to $33 Positive
- A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $31 to $35
- Barclays Maintains Progyny(PGNY.US) With Hold Rating, Maintains Target Price $34
- CCORF Maintains Progyny(PGNY.US) With Buy Rating, Cuts Target Price to $35 Negative
- BofA Securities Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $31
- J.P. Morgan Maintains Progyny(PGNY.US) With Hold Rating, Raises Target Price to $30 Positive
- Wells Fargo Initiates Progyny(PGNY.US) With Buy Rating, Announces Target Price $37
- Truist Financial Maintains Progyny(PGNY.US) With Buy Rating, Announces Target Price $36
- Barclays Maintains Progyny(PGNY.US) With Hold Rating, Cuts Target Price to $30 Negative
- CCORF Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $35
- Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Progyny (PGNY) and Adicet Bio (ACET)
- Barclays Downgrades Progyny(PGNY.US) to Hold Rating, Raises Target Price to $34 Mixed
- BTIG Maintains Progyny(PGNY.US) With Buy Rating, Raises Target Price to $40 Positive
- CCORF Maintains Progyny(PGNY.US) With Buy Rating, Raises Target Price to $36 Positive
- Leerink Partners Maintains Progyny(PGNY.US) With Buy Rating, Announces Target Price $38
No comments yet — be the first to weigh in on PGNY.
Sign in to join the discussion.